Airbnb CTO Aristotle Balogh to Depart-December 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Airbnb CTO Aristotle Balogh to Depart

Nov 21, 2025 11:57 AM

02:34 PM EST, 11/21/2025 (MT Newswires) -- Airbnb ( ABNB ) said in a regulatory filing Friday that its chief technology officer Aristotle Balogh will step down from his role in December.

Balogh will remain in an advisory, non-executive capacity through at least February 2026 to assist with the transition, the company said.

Shares were up 3.2% in recent trading.

Price: 115.18, Change: +3.63, Percent Change: +3.26

Previous page： BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp Next page： Chevron seeks diversified approach to refinery investment

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp

Sep 8, 2025

Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...

Chevron seeks diversified approach to refinery investment

Sep 8, 2025

SINGAPORE, Sept 8 (Reuters) - Chevron ( CVX ) is looking to have a balanced portfolio of refineries, Brant Fish, the U.S. major's president, international products, said at the APPEC event in Singapore. There'll be places like Korea where we go investment heavy in petrochemicals and in heavy oil upgrading, Fish said of the firm's existing investments. And then there'll...

Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study

Sep 8, 2025

04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed clinically meaningful and statistically significant improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period. The 92-patient study met its primary endpoint of improvements in mean...

AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial

Sep 8, 2025

04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...